Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Financial Statements
- Click here to download AMGEN Inc.'s Income Statement
- Click here to download AMGEN Inc.'s Balance Sheet
- Click here to download AMGEN Inc.'s Statement of Cash Flows
Key Info
- Industry: Biological Product (except Diagnostic) Manufacturing
- Sector: Manufacturing
- CEO Name: Robert Bradway
Key Statistics
- Stock Price: $252.42
- Dividend Yield: 3.1%
- Market Capitalization: $134,243,192,438
- Shares Outstanding: 533,579,206
- Number of Employees: 24,200
- Trailing 12-Month EPS: $12.48
- Trailing 12-Month DPS: $7.68
- Payout Ratio: 61.5%
Important Dates
- Next Earnings Date:
- Next Ex-Dividend Date: 2022-11-16
Price Trends
- Current Stock Price: $252.42
- 52-week high: $294.64
- 52-week low: $209.61
- 200-day moving average: $255.65
- 50-day moving average: $264.92
Performance
- 1-Month Price Return: -4.2%
- 3-Month Price Return: -7.5%
- 6-Month Price Return: 3.2%
- 1-Year Price Return: 13.3%
- 2-Year Price Return: 11.7%
- 5-Year Price Return: 53.6%
Visit the Passiv Stock Directory
Data provided by IEX Cloud
For Canadian securities, listen to free conference calls on the TSX Quarterly Podcast